<SEC-DOCUMENT>0001493152-22-024332.txt : 20220830
<SEC-HEADER>0001493152-22-024332.hdr.sgml : 20220830
<ACCEPTANCE-DATETIME>20220830060416
ACCESSION NUMBER:		0001493152-22-024332
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220830
FILED AS OF DATE:		20220830
DATE AS OF CHANGE:		20220830

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OKYO Pharma Ltd
		CENTRAL INDEX KEY:			0001849296
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41386
		FILM NUMBER:		221212838

	BUSINESS ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
		BUSINESS PHONE:		44 (0) 207 495 2379

	MAIL ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>August
2022</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:</B>&nbsp;001-41386</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>OKYO
Pharma LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>9<SUP>th</SUP>&nbsp;Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of registrant&rsquo;s principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(1): &#9744;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7): &#9744;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS REPORT ON FORM&nbsp;6-K</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 30, 2022, OKYO Pharma LTD (the &ldquo;<U>Company</U>&rdquo;) issued a news service announcement in the United Kingdom announcing
that OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing
Partner, AmbioPharm.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form&nbsp;6-K. The information in the attached Exhibit 99.1 is being
furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, or
otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall
be expressly set forth by specific reference in such a filing.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma LTD</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    August 30, 2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Gary Jacob</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
Jacob</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No.</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">News Service Announcement, dated August 30, 2022</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 108pt; width: 450pt"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing
Partner, AmbioPharm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101
    to treat ocular diseases, including Dry Eye Disease (DED), uveitis, allergic conjunctivitis, and ocular pain. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
    pre-IND meeting with FDA in Q1 2022 and novel speed to market potential.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IND
    filing on OK-101 to treat DED planned for Q4 2022, with first human trial designed as Phase 2 trial planned to begin in Q1 2023.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multibillion-dollar
    DED market whose medical needs remain largely unmet.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AmbioPharm
    supporting OK-101 program with peptide synthesis and development.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">London
and New York, N.Y., and North Augusta, S.C. 30 August 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>OKYO
Pharma Limited</U> (NASDAQ: OKYO; LSE: OKYO), a biotechnology company focused on the discovery and development of novel molecules to
treat inflammatory dry eye diseases and ocular pain, <B>plans a Q4 2022 IND filing for OK-101</B> to treat dry eye disease (DED), with
<U>AmbioPharm </U>playing a key role in peptide manufacturing and development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>OK-101
</U>is a lipid-peptide analog developed using a novel membrane-anchored peptide (MAP) technology. It consists of a 12 amino acid peptide
sequence, a linker component, and an anchoring lipid domain. OK-101 is designed to increase the potency and combat ocular washout through
the inclusion of the lipid &lsquo;anchor&rsquo; contained in the molecule to enhance the residence time within the ocular environment.
The OK-101 drug candidate displays potent anti-inflammatory activity in animal models of DED. OK-101 also reduces Corneal Neuropathic
Pain (CNP) in a ciliary nerve ligation animal model of CNP. Inflammation and pain are the two main symptoms of DED, and inflammation
is believed to be a major driver of the DED condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OK-101
has novel speed-to-market potential</B> by skipping a Phase I trial as the drug is administered topically, and by designing its Phase
2 trial effectively as a Phase 3 registration trial. Additionally, animal studies have shown no adverse effects of the drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Q1 2022, OKYO had a successful pre-IND meeting with the FDA and the FDA concurred with OKYO&rsquo;s plan to prespecify co-primary efficacy
endpoints of DED disease in the planned Phase 2 clinical trial. The Phase 2 trial, designed as effectively a Phase 3 registration trial,
if successful, <B>would accelerate the timeline to new drug application (NDA)</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DED
remains largely a major unmet medical need as approved drugs, to date, still leave many patients unsatisfied. Consequently, there is
multi-billion-dollar market potential for an effective drug with minimal side effects to treat this disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AmbioPharm
is supporting the OK-101 program with peptide synthesis and development</B>. A peptide contract development and manufacturing organization
(CDMO) providing cGMP peptide APIs with capabilities ranging from research to commercial scales, AmbioPharm actively engages with innovative
biopharmaceutical companies in developing first-in-class, best-in-class, and breakthrough peptide technologies that utilize AmbioPharm&rsquo;s
peptide manufacturing expertise and in-depth scientific experience in novel and conventional peptide chemistry. &ldquo;The OK-101 program
is a perfect fit for our dynamic business model, which helps our partners by providing high quality products and services with a highly
competitive cost structure,&rdquo; said Michael W. Pennington, Ph.D., Chief Scientific Officer of AmbioPharm Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We
are absolutely delighted to have AmbioPharm, a global leader in the synthesis of peptides and peptide analogs, manufacturing our drug
candidate OK-101,&rdquo; said Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO Pharma Ltd. &ldquo;The work performed by Ambiopharm
during this post-COVID 19 period to keep us on schedule with the manufacture of API went above and beyond the call of duty and was a
testament to the high standards that AmbioPharm abides by.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OKYO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
Pharma Limited (NASDAQ: OKYO; LSE: OKYO) is a life sciences and biotechnology company recently listed on Nasdaq and admitted to listing
on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities
of London Stock Exchange plc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
further information, please visit <U>www.okyopharma.com/</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
AmbioPharm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AmbioPharm,
a part of the Ambio Pharmaceuticals Group, is a leading and innovation-driven company specializing in the development and manufacture
of peptides and peptide-related products. With a comprehensive range of services, AmbioPharm produces custom products for research, clinical
development, and commercial application to pharmaceutical and biotechnology companies worldwide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
information is available at <U>www.ambiopharm.com.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward
Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
statements made in this announcement are forward-looking statements including with respect to the creation of a trading market for ADSs
representing the Ordinary Shares in the United States. These forward-looking statements are not historical facts but rather are based
on the Company&rsquo;s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such
as &ldquo;anticipates,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;seeks,&rdquo;
&ldquo;estimates&rdquo; and similar expressions are intended to identify forward-looking statements. These statements are not guarantees
of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company&rsquo;s
control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking
statements, including market conditions. We caution you therefore against relying on any of these forward-looking statements. Important
factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation,
our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any
infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and
commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other
factors relating to our industry, our operations and results of operations. . The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of
this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements
are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements
to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or
by any appropriate regulatory authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
S. Jacob, Ph.D., Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone:
(212) 209-3998</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AmbioPharm
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
DaFonseca, EVP, Sales &amp; Global Business Development</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>mark.dafonseca@ambiopharm.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Z E@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI"0H))  Y)-
M"T5D7GBC1+'(FU&$L/X8SO/_ ([FL2Y^(VFID6]K<3'U;" _S/Z5+DENQ71V
M5%>=S?$>[;_4:?"G^^Y;^6*J/X_UE\X6U3/]V,\?F364L1!"<T>GT5Y</'>M
M @EX#[&.K$/Q"U-3^]MK60>P93_.H^N4NI/M8GI-%<;9_$*SE8+>6DL'^TAW
MC^A_G74V6H6FHP^;9W"3)WVGD?4=16T*T)_"RE.,MF6:***T*"BBB@ HHHH
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M:$CMJ$D1D^4 JF!G:3G.[ SC'2MROE;P_KL]OXXL=:NYF>4WBR3R$\D,</\
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M_P"BY*\R^$7_ "4W2?I-_P"B7KWJTU_PCXQQ9Q76G:F5/F+;S(&.0/O!'&>
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M>'K(6FFVJPI_$W5G/JQZFM*O.G62]VDK+\3OC2;UJ.[_  $5510JJ%4#  &
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M5E)OM[A Z'O[@^X.0?I6=6*3YH[,N#Z,\$\!Z'HFO>/]>M]<@CF@3S7022E
M&\T#J".Q->G?\*Y^'O\ T#K3_P #)/\ XNO)/#'@^V\:>,/$-A/<26[Q>;+#
M(@! ;S<<CN.3Z50U7P5<>#=64>)K"YN-+8[5N;&4*#[@E2,_[)Q]:WDN:5E*
MQFG9;&WKVG:5X?\ B_HT'AAE6+S;<LD4QD".7(9<DD_=QQGO7MGC;_D1=?\
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M\/=/.,-.7F;\6('Z 5V=<9\-;C4%\,0:7J6DWEC/8KL#31[4E4DX*Y[CN/\
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MA1110!GZKH6E:XD::I807:Q$E!,F[:3UQ5V**."%(8D"1QJ%51T ' %/HHN
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M_EQ+@9/4_H*KZQX;T;7S =5TZ"[,!S&9!]WU_#VZ5J447=[A815"J%4 *!@
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MQ]W_ #FJ=":W%S([RBBBLB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
